Biomarin Pharmaceutical (BMRN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BMRN Biomarin Pharmaceutical

Watchlist

70.580
+0.340+0.48%

Close Sep 27 16:00 ET

69.988
-0.592-0.84%

Post 20:02 ET

13.44BMarket Cap53.47P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Goldman Sachs Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $139
Moomoo NewsSep 26 04:32 ET · Ratings
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Moomoo NewsSep 25 22:31 ET · Ratings
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Simply Wall StSep 25 10:53 ET
BioMarin Pharmaceutical Projects Strong Growth Through 2034
TipRanksSep 24 08:57 ET
Express News | Biomarin Pharmaceutical Inc: Reaffirming Its Long-Term Financial Guidance and Outlook That It Presented During Investor Day
ReutersSep 24 08:37 ET
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
BenzingaSep 23 10:00 ET

Comments

Moomoo AI

Mar 25 20:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

Moomoo AI

Mar 7 21:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Moomoo AI

Feb 8 22:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Jan 18 20:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 22, 2023 00:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

BMRN Biomarin Pharmaceutical

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target